
Opinion|Videos|May 29, 2024
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
Author(s)Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Advertisement
Related to this article

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
3
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
4
Contributor: Congress Can Bring Mental Health Care to the 21st Century
5

